Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action

Chuah, Kee Huat; Chan, Wah‐Kheong

doi:10.1111/apt.15700

Cited by 3 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is also supported by a recent FibroScan‐based study by Eris et al, which similarly reported NAFLD as the leading etiology of liver fibrosis at their center 26 . It is important to highlight as NAFLD can continue to contribute to liver disease progression in patients with other etiologies of CLD, which have been adequately treated 10,27–29 . Notably, NAFLD‐associated HCC is also markedly on the rise, concurrent with the rise in prevalence of NAFLD 30 .…”

Section: Discussionmentioning

confidence: 69%

Frequency of significant steatosis and compensated advanced chronic liver disease among adults with chronic liver disease

Shahrani,

Gill,

Sooi

et al. 2023

J of Gastro and Hepatol

Self Cite

View full text Add to dashboard Cite

BackgroundWith changes in the epidemiology and treatment of chronic liver disease (CLD), the impact of various etiologies of liver disease on steatosis and advanced fibrosis are uncertain.MethodsA retrospective study was conducted among liver disease patients of various etiologies undergoing transient elastography (TE) over a 9‐year duration.ResultsData for 2886 patients were analyzed and had the following demographics: The median age was 60 (IQR: 45–69) years, 51% were males, and ethnicity was predominantly Chinese (52.5%), followed by Malays (34%) and Indians (12.3%). The median CAP score was 272 (IQR: 219–319) dB/m and the median liver stiffness measurement (LSM) score was 6.5 (IQR: 4.9–9.7) kPa. Hepatic steatosis occurred across the spectrum of etiologies of CLD. Among patients with steatosis, the most common etiologies were nonalcoholic fatty liver disease (NAFLD) at 62% and chronic hepatitis B (CHB) at 26.3%. TE findings suggestive of cACLD (10.1–15 kPa) and highly suggestive of cACLD (>15 kPa) were observed in 11.3% and 12.4% of patients, respectively. NAFLD was found to be the most common etiology for cases with suggestive of cACLD (47.2%) and highly suggestive of cACLD (41.5%).ConclusionHepatic steatosis is common in CLD, regardless of etiology. Compared with other etiologies, NAFLD is now the leading cause of cACLD.

show abstract

Section: Discussionmentioning

confidence: 69%

Frequency of significant steatosis and compensated advanced chronic liver disease among adults with chronic liver disease

Shahrani,

Gill,

Sooi

et al. 2023

J of Gastro and Hepatol

Self Cite

View full text Add to dashboard Cite

show abstract

“…We thank Drs Chuah and Chan for their editorial on our study recently published in AP& T 1,2 . We agree that NAFLD and NASH represent a growing disease burden across many countries, with regional differences attributable to several factors.…”

mentioning

confidence: 73%

“…Porphyria cutanea tarda (PCT), the most common type of porphyria, 1,2 is due to decreased activity of hepatic uroporphyrinogen decarboxylase (UROD). A decrease greater than ~80% is necessary for PCT to become clinically manifest with the development of blisters and bullae on areas of skin exposed both to light and trauma, typically the backs of the hands and forearms.…”

Section: Editorial: Hepatitis C and Porphyria Cutanea Tarda In 2020mentioning

confidence: 99%

“…An acceptable therapeutic alternative is the use of low-dose hydroxychloroquine (HCQ). 1,2 Relapses after initial treatment are more likely in patients treated only with HCQ without iron reduction, especially in patients with hereditary haemochromatosis. 4 In recent years, infection with the hepatitis C virus has emerged as a major cause of active PCT.…”

Section: Editorial: Hepatitis C and Porphyria Cutanea Tarda In 2020mentioning

confidence: 99%

“…To view these articles, visit https://doi.org/10.1111/apt.15673 and https://doi.org/10.1111/apt.15700. Chris Estes 1 Henry L. Y. Chan 2,3 See Appendix A for the complete list of authors and affiliations.…”

Section: N K Ed Co Ntentmentioning

confidence: 99%

See 2 more Smart Citations

Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action. Authors' reply

Estes

Chan

Chien

et al. 2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Nonalcoholic Fatty Liver Disease: A Global Perspective

Wong

Chan

2021

Clinical Therapeutics

Self Cite

View full text Add to dashboard Cite

The prevalence of nonalcoholic fatty liver disease (NAFLD) has been increasing over the years and is now as high in Asia as in the Western world, so much so that it should no longer be considered a Western disease. In fact, China is expected to have the largest increase in the number of NAFLD cases in the coming years. The increase in prevalence of NAFLD in Asia lags behind that of the Western world; thus, there will be a lag in more severe liver disease in Asia despite a similar prevalence of the disease. NAFLD is more prevalent among patients with diabetes mellitus, which is also an important risk factor for more severe liver disease. Patients with diabetes mellitus thus represent an important target for screening for NAFLD and more severe liver disease. Although the PNPLA3 gene polymorphism is the most studied in NAFLD, it is increasingly clear that the cumulative effect of multiple genes likely predisposes to NAFLD and more severe liver disease in the different ethnic groups, and polygenic risk scores are emerging. Lean NAFLD has been largely reported in Asia but is increasingly recognized worldwide. Multiple risk factors have been identified for the disease that manifests in metabolically unhealthy normal weight individuals; however, it responds to lifestyle intervention, similar to the disease in obese individuals. Lastly, the newer term "metabolic dysfunctioneassociated fatty liver disease" provides a more accurate reflection of the disease, giving more focus to clinicians and researchers in tackling this increasingly common and challenging disease. (Clin Ther. 2021;43:473e499)

show abstract

Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action

Abstract: LINKED CONTENT This article is linked to Estes et al papers. To view these articles, visit https://doi.org/10.1111/apt.15673 and https://doi.org/10.1111/apt.15718.

Cited by 3 publications

References 10 publications

Frequency of significant steatosis and compensated advanced chronic liver disease among adults with chronic liver disease

Frequency of significant steatosis and compensated advanced chronic liver disease among adults with chronic liver disease

Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action. Authors' reply

Nonalcoholic Fatty Liver Disease: A Global Perspective

Contact Info

Product

Resources

About